Skip to main content

Table 3 Predictors of HCC recurrence

From: Hepatic resection versus microwave ablation for the treatment of early hepatocellular carcinoma: a comparative analysis of treatment outcomes and survival predictors

  HCC recurrence (count/%) P value
Recurrence No recurrence
Gender Female 3 (50%) 20 (30.3%) 0.376
Male 3 (50%) 46 (69.7%)
Smoking Yes 0 (0%) 19 (28.8%) 0.331
No 6 (100%) 47 (71.2%)
Diabetes mellitus Yes 2 (33.3%) 21 (31.8%) 1
No 4 (66.7%) 45 (68.2%)
Child score (mean/SD) 5.67 (0.82) 5.53 (0.64) 0.743
Hemoglobin (mean/SD) 12.27 (1.51) 13.02 (1.76) 0.232
Platelets (mean/SD) 146.67 (63.89) 165.45 (44.29) 0.684
AFP (baseline) (median/IQR) 59.75 (41–132) 43 (12–124) 0.293
AFP (post-ttt) (median/IQR) 100.8 (76.4–213) 12.75 (6.8–24.8) 0.011
Number of HFLs (mean/SD) 1.00 (0.0) 1.18 (0.46) 0.557
Size of HFLs (mean/SD) 3.15 cm (0.74) 3.48 cm (1.5) 0.570
Treatment modality Hepatectomy 3 (50%) 28 (42.4%) 1
Percutaneous microwave ablation 3 (50%) 34 (51.5%)
Intraoperative microwave ablation 0 (0%) 4 (6.1%)
Post-treatment portal vein thrombosis Yes 0 (0%) 1 (1.5%) 1
No 6 (100%) 65 (98.5%)
Post-treatment clinical decompensation Yes 1 (16.7%) 10 (15.2%) 1
No 5 (83.3%) 56 (84.8%)